TopFunds

Zoetis

NYSE: ZTS

Stock price

76.56 USD

(+Infinity%) NaN day

PharmaceuticalsDrug Manufacturers - General

Financial Performance

Share

5Y price score: (85)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 74.8%

DATE RANGE:

US$ Per
Share

    Time scale:

    By default your notes are visible only to you.

    71.4

    52-week range

    160.4

    76.56

    Your model inputs

    Required return / cost of capital
    %
    FCFF terminal growth rate
    %

    Your fair value & Margin of safety

    To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

    Forecast:

    Valuation

    Free Cash Flow Yield

    Help
    FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

    6.4 %

    Dividend Yield TTM

    2.7 %

    Market cap $

    $ 32,096

    Price / Earnings TTM

    Help
    P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

    12.7

    Price / Book TTM

    10

    PEG TTM

    Help
    Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

    1.3

    Earnings growth and return

    LTM

    5YR

    10YR

    Total return (price & dividends)

    (47.6) %

    (57.9) %

    74.8 %

    Free cash flow per share growth

    1.8 %

    47.1 %

    486.9 %

    Earnings per share growth

    10.1 %

    76 %

    785.3 %

    Founded: 1,952

    Employees: 13,800

    Business Summary:Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

    Fair Value Reference Estimate

    Latest Earnings Call Takeaways

    2026 Q1 (May 7, 2026)

    1) Strategy & Leadership
    - Zoetis reported flat organic operational revenue for Q1 2026, with adjusted net income growing 1%.
    - The company is focused on sharpening commercial execution and enhancing cost discipline to navigate current market challenges.
    - A comprehensive cost and productivity program has been launched to address growth softness, tightening discretionary spending, and improving operational efficiencies.
    - Zoetis is committed to long-term value creation, with a pipeline of 12 potential blockbusters expected to drive future growth.

    2) Financial & Segment Results
    - Global revenue for Q1 2026 was $2.3 billion, with a 3% increase on a reported basis but flat on an organic operational basis.
    - The International segment saw a 10% organic operational revenue growth, while the U.S. segment declined by 8%.
    - Livestock revenue grew 12% organically, while companion animal revenue declined 4%.
    - Key dermatology products reported an 11% decline, and the Simparica franchise saw a 1% decline in revenue.

    Metric Q1 2026 Results YoY Change
    Global Revenue $2.3 billion +3% (reported), 0% (organic)
    U.S. Revenue $1.1 billion -8%
    International Revenue $1.1 billion +10% (organic)
    Livestock Revenue $720 million +12%
    Companion Animal Revenue $1.5 billion -4%

    3) Problems / Headwinds
    - Increased price sensitivity among pet owners has led to lower clinic traffic and demand for premium products.
    - Competition has intensified, particularly in dermatology and parasiticides, with aggressive pricing strategies from new entrants.
    - The U.S. companion animal market is facing significant challenges, with a decline in routine veterinary visits and a shift towards lower-cost alternatives.
    - The company experienced a $100 million revenue shift from Q4 2025 to Q1 2026 due to fiscal year alignment, impacting organic growth comparisons.

    4) Operational or Product Plans
    - Zoetis is investing in targeted direct-to-consumer (DTC) activities and enhancing affordability options to address price sensitivity.
    - The company is advancing its product pipeline, including the launch of Cytopoint Plus and the acquisition of Neogen's animal genomics business to enhance livestock genetics.
    - Diagnostics remain a strong growth area, with international momentum and modest U.S. growth driven by reference lab expansion.
    - The company is focused on improving execution across its core commercial levers and optimizing its product portfolio in response to market dynamics.

    5) Guidance & Outlook / Investor Angle
    - For the full year 2026, Zoetis expects organic operational revenue growth of 2% to 5% and adjusted net income growth of 2% to 6%.
    - The company anticipates continued pressure in the U.S. companion animal portfolio but sees potential for recovery as market conditions stabilize.
    - The updated guidance reflects the current operating environment, with expectations for improved performance in the second half of the year.
    - Investors should note the potential for long-term growth driven by innovation and a diversified portfolio, despite near-term challenges.

    Bottom line: Zoetis is navigating a challenging market environment characterized by increased competition and price sensitivity among pet owners. While Q1 2026 results fell short of expectations, the company's diversified portfolio and strategic focus on innovation and cost discipline position it for potential recovery and long-term growth, making it a compelling option for shareholders.

    Annual Reports, Presentations And IR Contacts

    Go to the website
    Annual report links (10K)
    2025202420232022202120202019201820172016

    Zoetis — Financial Overview, Stock Price, Market Cap

    Zoetis is a company. Founded in 1952. As of July 20, 2026, the company's market capitalization is $32096104714 with a current stock price of $76.56.